ReviewSeminars in immunopathology2009
Colitis-associated cancer: the role of T cells in tumor development.
Review in Seminars in immunopathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 113 citations in OpenAlex.
- Review
- Inflammation and aging-related disease: A transdisciplinary inflammaging framework.GeroScience · 2025Review
- Inflammatory factors collaboratively linkFrontiers in immunology · 2025Review
- The linear ANRIL transcript P14AS regulates the NF-κB signaling to promote colon cancer progression.Molecular medicine (Cambridge, Mass.) · 2023Article
- Cupping Therapy as an Anti-inflammation Therapy and Immunomodulator in Cancer Patients.Journal of gastrointestinal cancer · 2023Article
- Research on the effect of interfering with miRNA-155 on triple-negative breast cancer cells.Genes & genomics · 2022Article
- NF-κB signaling in inflammation and cancer.MedComm · 2021Review
- Review
- A review of digital cytometry methods: estimating the relative abundance of cell types in a bulk of cells.Briefings in bioinformatics · 2021Review
- Article
- Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.Frontiers in immunology · 2021Review
- Data Driven Mathematical Model of Colon Cancer Progression.Journal of clinical medicine · 2020Article
- Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.Virchows Archiv : an international journal of pathology · 2020Article
- Complement and Cancer-A Dysfunctional Relationship?Antibodies (Basel, Switzerland) · 2020Review
- Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study.Signal transduction and targeted therapy · 2020Review
- Effect of TLR2 on the proliferation of inflammation-related colorectal cancer and sporadic colorectal cancer.Cancer cell international · 2020Article
- Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell.BMC complementary and alternative medicine · 2019Article
- Transcriptomics analysis reveals new insights in E171-induced molecular alterations in a mouse model of colon cancer.Scientific reports · 2018Article
- Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD.Nature reviews. Gastroenterology & hepatology · 2017Review
- Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), an anticancer agent, exerts an anti-inflammatory effect in activated human mast cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation severely increases the risk for cancer development as seen in patients with inflammatory bowel disease (IBD). Although the exact mechanisms of inflammation-associated tumor development remain to be shown, a role for the adaptive immune system has been implicated in colitis-associated cancer (CAC). In fact, CD4+ effector T cells, which promote chronic inflammation in IBD, create a tumor convenient environment, which can lead to cancer initiation, promotion, and progression. Thereby, the cytokines interleukin-6 and tumor necrosis factor-alpha constitute an important link between inflammation and tumor growth. Furthermore, cytotoxic CD8+ T cells, which usually are protective as part of the host antitumor immune response in sporadic cancer, can contribute to the aggravation of chronic inflammation and thereby support tumor development. In contrast, regulatory T cells, which have been shown to attenuate tumor immunosurveillance, act as potent suppressors of chronic inflammation and thus can have protective effects in CAC. This review discusses the role of the adaptive immune response and especially T cells in the pathogenesis CAC and possible implications for the therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.